-
Recent Posts:
Recent Comments:
- Rowena Dingwall on Why Do People With Advanced Cancer Undergo Chemotherapy?
- Daren Mearns on Contemplating Complementary Medicine
- Gregory Muller on MATH and Tumors
- ann stewart on If You Can’t Afford Your Medication
- colleen minchik on “Borne Out of Necessity and Data”: Conquering Mutations in Leukemia
Latest PLoG Posts
- This Week in PLOS Medicine: Iron Supplements during Pregnancy; Male-Male Consensual Sex, Sexual Violence, & HIV in South Africa; & Malaria Surveillance in Work In Progress
- What Is the Health Impact of Fracking? in Work In Progress
- Mind the Brain Podcast Episode 02: The Neuroscience of Music - Anticipation and Reward in Work In Progress
- Exploring multiple facets of modern men's health in Work In Progress
- Announcing ALM Reports - a new tool for analyzing Article Impact in Work In Progress
You may also be interested in:
Click to go to this PLOS Medicine collection
Category Archives: Cost-Effectiveness Analysis
Cancer Care’s “Culture of Excess”
Category: cancer, Cost-Effectiveness Analysis, Healthcare
Tagged biomarkers, cancer, cancer care, cancer cost, complex adaptive systems, European Multidisciplinary Cancer Congress, FiercePharma, incremental cost-effectiveness ratios, moral hazard, Richard Sullivan, The Huffington Post, The Lancet Oncology
3 Comments
Jessica Wapner is a freelance writer focused mainly on biomedical issues. Her work is published in Scientific American, The New York Times, Slate, Science, Nature Medicine, and elsewhere. Her first book, The Philadelphia Chromosome is forthcoming from The Experiment in May 2013.